ProShare Advisors
MRNS

ProShare Advisors’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

ProShare Advisors’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-10,724
Closed -$12.5K – 2150
2024
Q2 		$12.5K Sell
10,724
-2,938
-22% -$7.35K ﹤0.01% 1829
2024
Q1 		$124K Buy
13,662
+1,782
+15% +$17.3K ﹤0.01% 1786
2023
Q4 		$129K Buy
+11,880
New +$89K ﹤0.01% 1743
2022
Q2 		– Sell
-10,743
Closed -$100K – 2197
2022
Q1 		$100K Sell
10,743
-2,502
-19% -$24.9K ﹤0.01% 2033
2021
Q4 		$158K Buy
13,245
+665
+5% +$7.68K ﹤0.01% 2115
2021
Q3 		$143K Sell
12,580
-3,584
-22% -$49.3K ﹤0.01% 1854
2021
Q2 		$290K Buy
16,164
+3,448
+27% +$55.5K ﹤0.01% 1918
2021
Q1 		$197K Buy
12,716
+2,208
+21% +$31.9K ﹤0.01% 2049
2020
Q4 		$128K Buy
+10,508
New +$146K ﹤0.01% 1950
2020
Q3 		– Sell
-2,879
Closed -$29K – 1705
2020
Q2 		$29K Buy
+2,879
New +$26.5K ﹤0.01% 1648
2018
Q4 		– Sell
-5,245
Closed -$210K – 1731
2018
Q3 		$210K Sell
5,245
-211
-4% -$6K ﹤0.01% 1577
2018
Q2 		$154K Buy
5,456
+783
+17% +$17.4K ﹤0.01% 1666
2018
Q1 		$71K Sell
4,673
-773
-14% -$18.4K ﹤0.01% 1658
2017
Q4 		$178K Buy
+5,446
New +$147K ﹤0.01% 1665

Other funds holding MRNS

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

ProShare Advisors's MRNS Position: Q3 2024 in Review

ProShare Advisors sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q3 2024, closing a stake of 10,724 shares — an estimated $12.5K sold.

ProShare Advisors first reported a position in MRNS in Q4 2017 and held it in 14 quarters. The position peaked at $290K in Q2 2021. 75 funds tracked by Wall St. Rank hold MRNS as of Q3 2024.

  • ProShare Advisors reported no remaining Marinus Pharmaceuticals, Inc position as of Q3 2024 after selling out during the quarter.
  • ProShare Advisors sold 10,724 Marinus Pharmaceuticals, Inc shares in Q3 2024, an estimated $12.5K.
  • ProShare Advisors first reported a position in Marinus Pharmaceuticals, Inc in Q4 2017 and held it in 14 quarters.
  • ProShare Advisors's Marinus Pharmaceuticals, Inc position peaked at $290K in Q2 2021.
  • 75 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q3 2024.

Based on ProShare Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.